Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study

Chesney, Jason; D. Lewis, Karl; M. Kluger, Harriet; Hamid, Omid; D. Whitman, Eric; Thomas, Sajeve; Wermke, Martin; Cusnir, Mike; Domingo‐Musibay, Evidio; Q. Phan, Giao; M. Kirkwood, John; C. Hassel, Jessica; Orloff, Marlana; Larkin, James; S. Weber, Jeffrey; J.S. Furness, Andrew; I. Khushalani, Nikhil; Medina, Theresa; E. Egger, Michael; Graf Finckenstein, Friedrich; Jagasia, Madan; Hari, Parameswaran; Sulur, Giri; Shi, Wen; Wu, Xiao; A. Sarnaik, Amod

doi:10.1136/jitc-2022-005755

Public

Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study

Published in Journal for ImmunoTherapy of Cancer • Dec 1, 2022

Authors:

Jason Chesney

Karl D. Lewis

Harriet M. Kluger

Abstract

BACKGROUND: Patients with advanced melanoma have limited treatment options after progression on immune checkpoint inhibitors (ICI). Lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, demonstrated an investigator-assessed objective response rate (ORR) of 36% in 66 pat...

Subject

Medicine

Melanoma

Internal medicine

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!